Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1990 Jun;66(776):446–449. doi: 10.1136/pgmj.66.776.446

Efficacy of enalapril in essential hypertension and its comparison with atenolol.

M el Mangoush 1, N K Singh 1, S Kumar 1, A Basha 1, B S Gupta 1, Y K Bolya 1, A Gamati 1
PMCID: PMC2429599  PMID: 2216994

Abstract

The effect of enalapril was evaluated in 67 patients with essential hypertension, and its therapeutic efficacy was compared with atenolol in a placebo run-in, single-blind, cross-over trial. Enalapril significantly reduced blood pressure in all grades of essential hypertension. As monotherapy it 'normalized' blood pressure in 88%, 50% and 25% of patients with mild, moderate and severe hypertension respectively. Optimal dose for most of the patients was 20 to 40 mg/day. Comparison with atenolol revealed almost parallel efficacy of the two drugs, although enalapril produced a significantly greater reduction in systolic blood pressure in patients with mild and moderate hypertension (P less than 0.01 in each group). No serious side effects were encountered with either drug. Enalapril, therefore, has a potent and slightly superior antihypertensive effect to that of atenolol, and may be used as a 'first-step' drug in the treatment of hypertensive patients.

Full text

PDF
446

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergstrand R., Herlitz H., Johansson S., Berglund G., Vedin A., Wilhelmsson C., Gomez H. J., Cirillo V. J., Bolognese J. A. Effective dose range of enalapril in mild to moderate essential hypertension. Br J Clin Pharmacol. 1985 May;19(5):605–611. doi: 10.1111/j.1365-2125.1985.tb02687.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Davies R. O., Irvin J. D., Kramsch D. K., Walker J. F., Moncloa F. Enalapril worldwide experience. Am J Med. 1984 Aug 20;77(2A):23–35. doi: 10.1016/s0002-9343(84)80055-8. [DOI] [PubMed] [Google Scholar]
  3. Fouad F. M., Tarazi R. C., Bravo E. L., Textor S. C. Hemodynamic and antihypertensive effects of the new oral angiotensin-converting-enzyme inhibitor MK-421 (enalapril). Hypertension. 1984 Mar-Apr;6(2 Pt 1):167–174. [PubMed] [Google Scholar]
  4. Helgeland A., Strømmen R., Hagelund C. H., Tretli S. Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway. Lancet. 1986 Apr 19;1(8486):872–875. doi: 10.1016/s0140-6736(86)90985-2. [DOI] [PubMed] [Google Scholar]
  5. Kannel W. B., Dawber T. R., McGee D. L. Perspectives on systolic hypertension. The Framingham study. Circulation. 1980 Jun;61(6):1179–1182. doi: 10.1161/01.cir.61.6.1179. [DOI] [PubMed] [Google Scholar]
  6. Lichtenstein M. J., Shipley M. J., Rose G. Systolic and diastolic blood pressures as predictors of coronary heart disease mortality in the Whitehall study. Br Med J (Clin Res Ed) 1985 Jul 27;291(6490):243–245. doi: 10.1136/bmj.291.6490.243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Moncloa F., Sromovsky J. A., Walker J. F., Davies R. O. Enalapril in hypertension and congestive heart failure. Overall review of efficacy and safety. Drugs. 1985;30 (Suppl 1):82–89. doi: 10.2165/00003495-198500301-00012. [DOI] [PubMed] [Google Scholar]
  8. Simon A. C., Levenson J. A., Bouthier J. D., Benetos A., Achimastos A., Fouchard M., Maarek B. C., Safar M. E. Comparison of oral MK 421 and propranolol in mild to moderate essential hypertension and their effects on arterial and venous vessels of the forearm. Am J Cardiol. 1984 Mar 1;53(6):781–785. doi: 10.1016/0002-9149(84)90403-x. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES